Objective Explore the inhibitory effect of 17-DMAG on the growth and angiogenesis of PD-1 humanized mouse liver cancer transplantation tumor. Methods 30 PD-1 humanized mice were selected and human HepG2 cell suspension was injected into the subcutaneous tissue of the right inguinal region of the mice to construct a human liver cancer transplant tumor model. Tumor bearing humanized mice were randomly divided into three groups (10 mice per group): ① model group (injected with 10 mg/kg of physiological saline); ② 17-DMAG group (intraperitoneal injection of 17-DMAG at 25 mg/kg, 3 times/week); ③ The cisplatin group (intraperitoneal injection of 20 mg/kg, 2 times per week), the experiment lasted for 4 week. After injection, the length and short diameter of the humanized mouse transplanted tumor were measured to calculate the volume, and the tumor mass were measured to calculate to calculate the tumor inhibition rate. At the same time, immunohistochemical methods were used to detect the expression of CD31 (tumor microvessel density, MVD) and vascular endothelial growth factor (VEGF) in tumor tissue. Results The tumor volume and mass of the 17-DMAG group and the cisplatin group were significantly reduced compared to the model group (P<0.05), and the tumor inhibition rate of the 17-DMAG group was slightly higher than that of the cisplatin group. However, there was no significant difference in tumor mass, volume, and tumor inhibition rate between the 17-DMAG group and the cisplatin group. The number of MVD labeled microvessels and VEGF expression in the 17-DMAG group and cisplatin group were lower than those in the model group (P<0.05), and the 17-DMAG group was also lower than those in the cisplatin group (P<0.05). Conclusions 17-DMAG can inhibit the growth of humanized mouse liver cancer xenografts by reducing the expression of vascular endothelial growth factor in liver cancer xenograft tissue, thereby inhibiting the generation of tumor neovascularization.